BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 12, 2025
Home » Keywords » Versant Ventures

Items Tagged with 'Versant Ventures'

ARTICLES

Blue dollar sign on white background
Newco news

Granite Bio emerges with $100M raised and two immunology assets

April 24, 2025
By Karen Carey
Named after Swiss mountains, Granite Bio AG emerged from stealth with $70 million in funds through a series B to advance two immunology treatments incubated at Versant Ventures.
Read More
Endocrine/metabolic

Pep2tango Therapeutics advances tetra-agonists for obesity

Nov. 22, 2024
Startup company Pep2tango Therapeutics Inc., unveiled with backing by Versant Ventures, is advancing unimolecular multireceptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors.
Read More

Novartis acquires gene therapy developer Kate Therapeutics for $1.1B

Nov. 21, 2024
By Karen Carey
Rising from a $51 million series A round a year ago to a $1.1 billion acquisition, Kate Therapeutics Inc. has stepped under the umbrella of Novartis AG, which gains preclinical adeno-associated virus-based gene therapies for neuromuscular diseases.
Read More
Hand adjusting gears
Newco news

Borealis from Novartis is born from the remains of Chinook

Aug. 22, 2024
By Lee Landenberger
There was more juice to be extracted from the grape that was the very successful Chinook Therapeutics Inc., so two investors have decided to make the most of it. Novartis AG and Versant Ventures have launched Borealis Biosciences Inc. from Chinook’s remnants to develop RNA therapies for treating kidney disease.
Read More
Grey dollar sign on grey background
Drug Design, Drug Delivery & Technologies

Gate golden with $60M series A to build new bridge in protein degradation

Nov. 8, 2023
By Randy Osborne
Gate Bioscience Inc., a new(ish) company with a new class of drugs in the works, emerged from stealth mode and disclosed a $60 million series A financing led by Versant Ventures and A16z Bio + Health. Arch Venture Partners and GV took part in the financing as well.
Read More
Grey dollar sign on grey background

Gate golden with $60M series A to build new bridge in protein degradation

Nov. 1, 2023
By Randy Osborne
Gate Bioscience Inc., a new(ish) company with a new class of drugs in the works, emerged from stealth mode and disclosed a $60 million series A financing led by Versant Ventures and A16z Bio + Health. Arch Venture Partners and GV took part in the financing as well.
Read More
Targets with arrows
Newco news

Nexo emerges with $60M series A, takes aim at ‘elusive’ targets

Aug. 4, 2023
By Jennifer Boggs
When looking for a name, the founders of startup Nexo Therapeutics Inc., which recently emerged from stealth mode with a $60 million series A financing and a research collaboration with the University of Texas MD Anderson Cancer Center, sought a moniker that truly captured its approach to drug development.
Read More
Molecule illustration

$2B+ Genentech deal propels Belharra to the crest of the chemoproteomics wave

Jan. 4, 2023
By Cormac Sheridan
Belharra Therapeutics Inc., an early stage firm which is pioneering a new approach to chemoproteomics, has already found an influential backer for the distinctive way it systematically probes the interactions between small-molecule ligands and the proteins to which they bind.
Read More
DNA illustration

Vector Biopharma closes $30M series A round to support new gene therapy vector

Aug. 10, 2022
By Cormac Sheridan
Vector Biopharma AG has secured a $30 million series A funding commitment from founding investor Versant Ventures to take forward a new gene delivery platform developed by Andreas Plückthun, of the University of Zurich, in Switzerland.
Read More
Dollar sign in light bulb on yellow background

Cimeio ‘points’ the way to safer cell therapy with $50M series A round

April 13, 2022
By Cormac Sheridan
Versant Ventures is committing $50 million in series A funding to Cimeio Therapeutics Inc., which aims to bring new possibilities in terms of disease targeting and safety to bear on a wide range of cell therapy applications, including hematopoietic stem cell transplantation (HSCT) and adoptive cell transfer.
Read More
More Articles Tagged with 'Versant Ventures'

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 6, 2025
  • Digital globe illustrating pharma trade, tariffs

    Navigating the Trump tariffs, part two: Amgen, Biogen, others

    BioWorld
    As biopharma companies continue to roll out their first-quarter  earnings, Trump administration tariffs remain at the top of investors’ minds. While executives...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing